NewsMavens
Newsmavens is a media start-up within Gazeta Wyborcza, Poland's largest liberal broadsheet published by Agora S.A. Newsmavens is currently financed by Gazeta Wyborcza and Google DNI Fund. Gazeta Wyborcza, Agora SA Czerska 8/10
00-732, Warsaw
Poland
Core team_
Zuzanna Ziomecka
Zuzanna Ziomecka EDITOR IN CHIEF
Lea Berriault-Jauvin
Lea Berriault Managing Editor
NEWS ROUNDUP 12 Feb 2018

Word choice matters when reporting on autism treatments

Tijana Cvjeticanin recommended by Tijana Cvjeticanin Istinomjer, Bosnia and Herzegovina

A new drug could be a breakthrough in treating symptoms of autism spectrum disorder. But Balkan media outlets have misled the public by saying the drug is a "cure for autism."

Bosnia and Herzegovina Aha moments

Why this story matters:

Public discourse on autism is packed with manipulations and misconceptions. Autism Spectrum Disorder (ASD) is often falsely described as an illness caused by vaccines or a reaction to non-existent "parasites," untraceable to modern medicine.

Parents of children with ASD sometimes fall prey to advertisements of unethical, unsafe and untested practices, presented to them as medicine.

These irrational narratives are frequently supported by media, including those in the Balkans. Spectacular fairy tales of "regular moms who defeated autism in their children" contribute to the stigmatization of people with ASD and the spread of dangerous practices.

In an online environment crawling with charlatans, the media's choice of words to translate "autism drug" could feed dangerous misconceptions. A drug is not the same as the cure, nor is "treatment of symptoms" equal to "curing" a neurological disorder.

health,family,media,science

Details from the story:

  • Pharmaceutical company Roche recently announced that the U.S. Food and Drug Administration  granted a "breakthrough therapy designation" for a new drug they are developing.
  • The designation recognizes the drug's potential, shows intent to cooperate with the manufacturer in the testing process, and takes the drug to market if clinical trials are successful.
  • Early tests show the drug, called Balovaptan, may reduce core symptoms of ASD, specifically difficulties in social interaction and communication. 
  • Balkan media outlets presented news about Balovaptan in a misleading way, such as it was already approved by the FDA and that it could "cure autism."
  • The words "drug" and "cure" are interchangeable in local language, and "breakthrough therapy designation" is difficult to translate, so some media outlets used "approval" in their headlines.

ALSO IN THE NEWS ROUNDUP 12 Feb 2018
weekly hindsight12-16 Feb 2018

It’s not enough to have women in power

read on
STORIES FROM ACROSS EUROPE SENT STRAIGHT TO YOUR INBOX
WITH FINANCIAL SUPPORT FROM:
SUPPORTED BY:
Google DNI Women in news World Editors Forum
STRATEGIC PARTNERS: